Limits...
AMPK Activation by A-769662 Controls IL-6 Expression in Inflammatory Arthritis.

Guma M, Wang Y, Viollet B, Liu-Bryan R - PLoS ONE (2015)

Bottom Line: Many studies have suggested that AMPK activation exert significant anti-inflammatory and immunosuppressive effects.The effect of A-769662 on bone marrow derived macrophage (BMDM) response to stimulation with TLR2 and TLR4 agonists was tested in vitro.IL-6 expression at both mRNA and protein levels, phosphorylation of p65 NF-κB and MAPK phosphorylation were inhibited by A-769662 in BMDMs stimulated with either TLR2 or TLR4 agonists.

View Article: PubMed Central - PubMed

Affiliation: Division of Rheumatology, Allergy and Immunology, UC San Diego School of Medicine, La Jolla, California, United States of America.

ABSTRACT

Objective: AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase critically involved in the regulation of cellular energy homeostasis. It is a central regulator of both lipid and glucose metabolism. Many studies have suggested that AMPK activation exert significant anti-inflammatory and immunosuppressive effects. In this study, we assessed whether targeted activation of AMPK inhibits inflammatory arthritis in vivo.

Methods: We tested the effect of A-769662, a specific AMPK agonist (60mg/kg/bid) in mouse models of antigen-induced arthritis (AIA) and passive K/BxN serum-induced arthritis. The passive K/BxN serum-induced arthritis model was also applied to AMPKα1-deficient mice. Joints were harvested and subjected to histological analysis. IL-6 expression was measured in both joint tissues and sera by ELISA. The effect of A-769662 on bone marrow derived macrophage (BMDM) response to stimulation with TLR2 and TLR4 agonists was tested in vitro.

Results: AMPK activation by A-769662 reduced inflammatory infiltration and joint damage in both mouse models. IL-6 expression in serum and arthritic joints was significantly decreased in A-769662-treated mice. AMPKα1 deficient mice mildly elicited an increase of clinical arthritis. IL-6 expression at both mRNA and protein levels, phosphorylation of p65 NF-κB and MAPK phosphorylation were inhibited by A-769662 in BMDMs stimulated with either TLR2 or TLR4 agonists.

Conclusions: AMPK activation by specific AMPK agonist A-769662 suppressed inflammatory arthritis in mice as well as IL-6 expression in serum and arthritic joints. These data suggest that targeted activation of AMPK has a potential to be an effective therapeutic strategy for IL-6 dependent inflammatory arthritis.

No MeSH data available.


Related in: MedlinePlus

A-769662 treatment abrogated joint damage and IL-6 expression in passive K/BxN arthritis.(A) Representative H&E and Safranin O stained sections of ankle joints on day 7 of arthritis induction in DMSO and A-769662-treated mice. Magnification 200x original. Black arrows in H&E stained sections show joint inflammation and white arrows in Safranin O stained sections show cartilage damage that was reduced in A-769662-treated ankles. (B) Histological scores for joint inflammation, erosion and cartilage damage in vehicle and high dose A-769662-treated mice on day 7 after serum transfer. (C) Proteins of joint tissues from naive (n = 3 mice per group) and arthritic mice (n = 5 mice per group) of DMSO and A-769662-treated mice were extracted and analyzed by ELISA for the presence of the indicated cytokines.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4608670&req=5

pone.0140452.g004: A-769662 treatment abrogated joint damage and IL-6 expression in passive K/BxN arthritis.(A) Representative H&E and Safranin O stained sections of ankle joints on day 7 of arthritis induction in DMSO and A-769662-treated mice. Magnification 200x original. Black arrows in H&E stained sections show joint inflammation and white arrows in Safranin O stained sections show cartilage damage that was reduced in A-769662-treated ankles. (B) Histological scores for joint inflammation, erosion and cartilage damage in vehicle and high dose A-769662-treated mice on day 7 after serum transfer. (C) Proteins of joint tissues from naive (n = 3 mice per group) and arthritic mice (n = 5 mice per group) of DMSO and A-769662-treated mice were extracted and analyzed by ELISA for the presence of the indicated cytokines.

Mentions: Next, we tested the effect of A-769662 on inflammatory arthritis in mice in vivo. We first used the K/BxN passive serum transfer model, which is dependent on innate but not adaptive immunity [13]. We observed that phosphorylation of AMPKα and acetyl-CoA carboxylase (ACC), an AMPK downstream target, in arthritic joint tissues decreased during the peak of inflammation at day 5 (Fig 3A and S2 Fig), but was increased in mice treated with A-769662 (Fig 3A). We used two different doses (30mg/kg/bid and 60mg/kg/bid) of A-769662. As shown in Fig 3B and 3C, higher dose of A-769662 significantly lowered clinical score at day 7, and ankle swelling from day 3. Histopathological analysis at day 7 showed reduced inflammatory cell infiltration, joint destruction and cartilage damage in A-769662-treated mice compared with vehicle-treated controls (Fig 4A and 4B). To evaluate the influence of A-769662 on synovial inflammatory mediators, we determined IL-6 and IL-1β production from these mice on day 5. Clinical score at day 5 was 12 ± 0.4 and 5.5 ± 1.3 for DMSO and A-769662-treated mice (0 = 0.002), respectively. Interestingly, amounts of IL-6, but not IL-1β, were significantly lower in A-769662-treated mice (Fig 4C), suggesting an important role of activation of AMPK in suppression of IL-6 expression.


AMPK Activation by A-769662 Controls IL-6 Expression in Inflammatory Arthritis.

Guma M, Wang Y, Viollet B, Liu-Bryan R - PLoS ONE (2015)

A-769662 treatment abrogated joint damage and IL-6 expression in passive K/BxN arthritis.(A) Representative H&E and Safranin O stained sections of ankle joints on day 7 of arthritis induction in DMSO and A-769662-treated mice. Magnification 200x original. Black arrows in H&E stained sections show joint inflammation and white arrows in Safranin O stained sections show cartilage damage that was reduced in A-769662-treated ankles. (B) Histological scores for joint inflammation, erosion and cartilage damage in vehicle and high dose A-769662-treated mice on day 7 after serum transfer. (C) Proteins of joint tissues from naive (n = 3 mice per group) and arthritic mice (n = 5 mice per group) of DMSO and A-769662-treated mice were extracted and analyzed by ELISA for the presence of the indicated cytokines.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4608670&req=5

pone.0140452.g004: A-769662 treatment abrogated joint damage and IL-6 expression in passive K/BxN arthritis.(A) Representative H&E and Safranin O stained sections of ankle joints on day 7 of arthritis induction in DMSO and A-769662-treated mice. Magnification 200x original. Black arrows in H&E stained sections show joint inflammation and white arrows in Safranin O stained sections show cartilage damage that was reduced in A-769662-treated ankles. (B) Histological scores for joint inflammation, erosion and cartilage damage in vehicle and high dose A-769662-treated mice on day 7 after serum transfer. (C) Proteins of joint tissues from naive (n = 3 mice per group) and arthritic mice (n = 5 mice per group) of DMSO and A-769662-treated mice were extracted and analyzed by ELISA for the presence of the indicated cytokines.
Mentions: Next, we tested the effect of A-769662 on inflammatory arthritis in mice in vivo. We first used the K/BxN passive serum transfer model, which is dependent on innate but not adaptive immunity [13]. We observed that phosphorylation of AMPKα and acetyl-CoA carboxylase (ACC), an AMPK downstream target, in arthritic joint tissues decreased during the peak of inflammation at day 5 (Fig 3A and S2 Fig), but was increased in mice treated with A-769662 (Fig 3A). We used two different doses (30mg/kg/bid and 60mg/kg/bid) of A-769662. As shown in Fig 3B and 3C, higher dose of A-769662 significantly lowered clinical score at day 7, and ankle swelling from day 3. Histopathological analysis at day 7 showed reduced inflammatory cell infiltration, joint destruction and cartilage damage in A-769662-treated mice compared with vehicle-treated controls (Fig 4A and 4B). To evaluate the influence of A-769662 on synovial inflammatory mediators, we determined IL-6 and IL-1β production from these mice on day 5. Clinical score at day 5 was 12 ± 0.4 and 5.5 ± 1.3 for DMSO and A-769662-treated mice (0 = 0.002), respectively. Interestingly, amounts of IL-6, but not IL-1β, were significantly lower in A-769662-treated mice (Fig 4C), suggesting an important role of activation of AMPK in suppression of IL-6 expression.

Bottom Line: Many studies have suggested that AMPK activation exert significant anti-inflammatory and immunosuppressive effects.The effect of A-769662 on bone marrow derived macrophage (BMDM) response to stimulation with TLR2 and TLR4 agonists was tested in vitro.IL-6 expression at both mRNA and protein levels, phosphorylation of p65 NF-κB and MAPK phosphorylation were inhibited by A-769662 in BMDMs stimulated with either TLR2 or TLR4 agonists.

View Article: PubMed Central - PubMed

Affiliation: Division of Rheumatology, Allergy and Immunology, UC San Diego School of Medicine, La Jolla, California, United States of America.

ABSTRACT

Objective: AMP-activated protein kinase (AMPK) is a serine/threonine protein kinase critically involved in the regulation of cellular energy homeostasis. It is a central regulator of both lipid and glucose metabolism. Many studies have suggested that AMPK activation exert significant anti-inflammatory and immunosuppressive effects. In this study, we assessed whether targeted activation of AMPK inhibits inflammatory arthritis in vivo.

Methods: We tested the effect of A-769662, a specific AMPK agonist (60mg/kg/bid) in mouse models of antigen-induced arthritis (AIA) and passive K/BxN serum-induced arthritis. The passive K/BxN serum-induced arthritis model was also applied to AMPKα1-deficient mice. Joints were harvested and subjected to histological analysis. IL-6 expression was measured in both joint tissues and sera by ELISA. The effect of A-769662 on bone marrow derived macrophage (BMDM) response to stimulation with TLR2 and TLR4 agonists was tested in vitro.

Results: AMPK activation by A-769662 reduced inflammatory infiltration and joint damage in both mouse models. IL-6 expression in serum and arthritic joints was significantly decreased in A-769662-treated mice. AMPKα1 deficient mice mildly elicited an increase of clinical arthritis. IL-6 expression at both mRNA and protein levels, phosphorylation of p65 NF-κB and MAPK phosphorylation were inhibited by A-769662 in BMDMs stimulated with either TLR2 or TLR4 agonists.

Conclusions: AMPK activation by specific AMPK agonist A-769662 suppressed inflammatory arthritis in mice as well as IL-6 expression in serum and arthritic joints. These data suggest that targeted activation of AMPK has a potential to be an effective therapeutic strategy for IL-6 dependent inflammatory arthritis.

No MeSH data available.


Related in: MedlinePlus